Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease
Sign Up to like & getrecommendations! Published in 2020 at "Medicina Clinica"
DOI: 10.1016/j.medcle.2019.07.012
Abstract: Abstract Introduction CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX antibodies is now considered part of the integral management.… read more here.
Keywords: week; response; disease; management ... See more keywords